Aerovate Therapeutics, Inc.

As of June 20, 2025, the market trend is mildly bearish, supported by bearish MACD and moving averages, despite some bullish signals from the RSI and OBV, indicating a cautious outlook.

Aerovate Therapeutics, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $3 million and a market cap of $7.64 million. Key metrics include a negative P/E ratio, a 0.00% dividend yield, and a return on equity of -65.24%.

As of Jun 18, Aerovate Therapeutics, Inc. has a market capitalization of 7.64 million, categorizing it as a Micro Cap company, with net sales of 0.00 million and a net profit of -48.96 million for the latest four quarters.